{"title":"Effects of Triphala on Lipid and Glucose Profiles and Anthropometric Parameters: A Systematic Review.","authors":"Wiraphol Phimarn, Bunleu Sungthong, Hiroyuki Itabe","doi":"10.1177/2515690X211011038","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>The efficacy of triphala on lipid profile, blood glucose and anthropometric parameters and its safety were assessed.</p><p><strong>Methods: </strong>Databases such as PubMed, ScienceDirect, Web of Science, and Thai Library Integrated System (ThaiLIS) were systematically searched to review current evidence of randomized controlled trials (RCT) on triphala. RCTs investigating the safety and efficacy of triphala on lipid profile, blood glucose and anthropometric parameters were included. Study selection, data extraction, and quality assessment were performed independently by 2 authors.</p><p><strong>Results: </strong>Twelve studies on a total of 749 patients were included. The triphala-treated groups showed significantly reduced low-density lipoprotein-cholesterol, total cholesterol and triglyceride in 6 studies. Five RCTs demonstrated triphala-treated groups led to statistically significant decrease in body weight, body mass index and waist circumference of obese patients. Moreover, triphala significantly decreased fasting blood glucose level in diabetic patients but not in people without diabetes. No serious adverse event associated with triphala was reported during treatment.</p><p><strong>Conclusions: </strong>This review summarized a current evidence to show triphala might improve the lipid profile, blood glucose, the body weight, body mass index and waist circumference under certain conditions. However, large well-designed RCTs are required to confirm this conclusion.</p>","PeriodicalId":15714,"journal":{"name":"Journal of Evidence-based Integrative Medicine","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2515690X211011038","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Evidence-based Integrative Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2515690X211011038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 9
Abstract
Aim: The efficacy of triphala on lipid profile, blood glucose and anthropometric parameters and its safety were assessed.
Methods: Databases such as PubMed, ScienceDirect, Web of Science, and Thai Library Integrated System (ThaiLIS) were systematically searched to review current evidence of randomized controlled trials (RCT) on triphala. RCTs investigating the safety and efficacy of triphala on lipid profile, blood glucose and anthropometric parameters were included. Study selection, data extraction, and quality assessment were performed independently by 2 authors.
Results: Twelve studies on a total of 749 patients were included. The triphala-treated groups showed significantly reduced low-density lipoprotein-cholesterol, total cholesterol and triglyceride in 6 studies. Five RCTs demonstrated triphala-treated groups led to statistically significant decrease in body weight, body mass index and waist circumference of obese patients. Moreover, triphala significantly decreased fasting blood glucose level in diabetic patients but not in people without diabetes. No serious adverse event associated with triphala was reported during treatment.
Conclusions: This review summarized a current evidence to show triphala might improve the lipid profile, blood glucose, the body weight, body mass index and waist circumference under certain conditions. However, large well-designed RCTs are required to confirm this conclusion.
目的:评价triphala对血脂、血糖、人体测量指标的影响及其安全性。方法:系统检索PubMed、ScienceDirect、Web of Science和Thai Library Integrated System (thailand)等数据库,回顾有关triphala的随机对照试验(RCT)的现有证据。本研究纳入了调查triphala对血脂、血糖和人体测量参数的安全性和有效性的随机对照试验。研究选择、数据提取和质量评估由2位作者独立完成。结果:12项研究共纳入749例患者。在6项研究中,triphala治疗组显示低密度脂蛋白胆固醇、总胆固醇和甘油三酯显著降低。五项随机对照试验显示,服用三氟组肥胖患者的体重、体重指数和腰围均有统计学意义的下降。此外,triphala显著降低了糖尿病患者的空腹血糖水平,而非糖尿病患者则没有。治疗期间未见与triphala相关的严重不良事件。结论:本文综述了目前有证据表明,在一定条件下,三联麻可能改善血脂、血糖、体重、体重指数和腰围。然而,需要大量设计良好的随机对照试验来证实这一结论。